CDC surveillance data show clinical Candida auris cases more than doubled from 2022 to 2024, with the fungus now classified as an urgent antimicrobial resistance threat. The report links the increase to ongoing hospital and long-term care transmission, where C. auris can persist on surfaces and be carried by colonized patients. The update also notes that detection and screening changes may have contributed to part of the rise, but the underlying concern remains that containment in healthcare settings is struggling against rapid spread. For biotech and hospital stakeholders, the growing burden raises pressure on diagnostics, infection control workflows, and antifungal development, particularly for settings where resistance and persistent colonization complicate eradication strategies.